文献速递免疫规划卫生政策与健康促进

美国老年人中在研成人配方肺炎球菌疫苗的成本效果

Cost-effectiveness of an in-development adult-formulated pneumococcal vaccine in older US adults.
PubMed 文献 · Vaccine · 2023-06-12

研究采用马尔可夫决策模型,比较现行肺炎球菌疫苗接种建议与在研21价肺炎球菌结合疫苗(PCV21)在65岁黑人及非黑人队列中的成本效果。PCV21策略在黑人队列每获得一个质量调整生命年(QALY)需花费88,478美元(无儿童PCV15间接效应)和97,952美元(有间接效应),非黑人队列为127,436美元和141,358美元;现行建议策略在经济上均不利。作者认为PCV21可能在经济和临床方面优于现行推荐疫苗。

要点

  • 在黑人65岁队列中,PCV21策略每QALY成本为88,478美元(无儿童PCV15间接效应)和97,952美元(有间接效应)。
  • 在非黑人65岁队列中,PCV21策略每QALY成本为127,436美元(无儿童PCV15间接效应)和141,358美元(有间接效应)。
  • 现行推荐接种策略在不同人群和有无儿童接种间接效应下均经济不利。

核心结论

  • 在研PCV21疫苗在美国老年人中可能较现行推荐肺炎球菌疫苗更具经济性和临床优势。
  • PCV21在黑人队列分析中更有利,但黑人和非黑人人群结果均在经济上合理,提示成人特异性肺炎球菌疫苗配方的潜在重要性,并可能在进一步研究后支持未来对老年人使用PCV21的普通人群推荐。

研究设计与样本

  • 马尔可夫决策模型,比较现行肺炎球菌疫苗接种建议与PCV21在黑人及非黑人65岁队列中的使用。
  • 人群及血清型特异性肺炎球菌疾病风险采用CDC主动细菌核心监测数据。
  • 疫苗有效性采用德尔菲专家组估计和临床试验数据,并在敏感性分析中变化。
  • 检查了儿童PCV15接种对成人疾病的潜在间接效应;所有模型参数在敏感性分析中逐一和集体变化。
  • 还检查了PCV21有效性降低和COVID-19大流行潜在影响的情景。

主要发现

  • 黑人队列中,PCV21策略每获得一个QALY的成本为88,478美元(无儿童PCV15间接效应)和97,952美元(有儿童PCV15间接效应)。
  • 非黑人队列中,PCV21策略每获得一个QALY的成本为127,436美元(无儿童PCV15间接效应)和141,358美元(有儿童PCV15间接效应)。
  • 现行推荐策略无论人群或儿童接种间接效应如何,均经济不利。
  • 支持使用PCV21的结果在敏感性分析和替代情景中稳健。

临床怎么用

  • 作者认为,在研PCV21疫苗可能较现行推荐肺炎球菌疫苗在美国老年人中更具经济和临床优势。
  • 作者指出,PCV21在黑人队列分析中更有利,但黑人和非黑人人群结果均在经济上合理,并可能在进一步研究后支持未来对老年人使用PCV21的普通人群推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: CDC pneumococcal vaccination recommendations for older adults now include either 15- or 20-valent pneumococcal conjugate vaccine (PCV15/PCV20). However, an in-development 21-valent vaccine (PCV21), formulated based on adult pneumococcal disease epidemiology, could substantially increase coverage of disease-causing pneumococcal serotypes, particularly in Black older adults, who are at greater risk. The potential public health impact and cost-effectiveness of PCV21 compared to currently recommended vaccines in older adults is unclear. METHODS: A Markov decision model compared current pneumococcal vaccination recommendations to PCV21 use in Black and non-Black 65-year-old cohorts. CDC Active Bacterial Core surveillance data informed population and serotype-specific pneumococcal disease risk. Vaccine effectiveness was estimated using Delphi panel estimates and clinical trial data, with variation in sensitivity analyses. Potential indirect effects on adult disease from PCV15 childhood vaccination were examined. All model parameters were varied individually and collectively in sensitivity analyses. Scenarios with decreased PCV21 effectiveness and potential COVID-19 pandemic effects were also examined. RESULTS: In the Black cohort, the PCV21 strategy cost $88,478 per quality adjusted life-year (QALY) gained without and $97,952/QALY with childhood PCV15 indirect effects. PCV21 in the non-Black cohort cost $127,436/QALY gained without and $141,358/QALY with childhood PCV15 effects. Current recommendation strategies were economically unfavorable, regardless of population or indirect childhood vaccination effects. Results favoring PCV21 use were robust in sensitivity analyses and alternative scenarios. CONCLUSION: An in-development PCV21 vaccine would likely be economically and clinically favorable compared to currently recommended pneumococcal vaccines in older adults. While PCV21 was more favorable in Black cohort analyses, results for both Black and non-Black populations were economically reasonable, highlighting the potential importance of adult-specific pneumococcal vaccine formulations and, pending further investigation, potentially justifying a future general population recommendation for PCV21 use in older adults.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Wateska AR, Nowalk MP, Lin CJ, et al. Cost-effectiveness of an in-development adult-formulated pneumococcal vaccine in older US adults. Vaccine. 2023. PMID: 37316409. doi:10.1016/j.vaccine.2023.06.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。